Yes — the active ingredient is metabolized by a gene known to vary between individuals.
Relevant genes: CYP2D6
Used for: Schizophrenia, bipolar disorder, major depressive disorder (as add-on), Tourette syndrome, autism-associated irritabilityGene2Rx covers this medication using the same CPIC and FDA guidelines GeneSight uses, costs $5-$49 instead of several hundred, and works with your existing 23andMe data.
Abilify (aripiprazole) is a second-generation antipsychotic with a broad indication profile, from schizophrenia and bipolar mania down to augmentation of SSRIs in treatment-resistant depression. Its clearance is dominated by CYP2D6, with CYP3A4 as a secondary pathway. That means CYP2D6 poor metabolizers accumulate aripiprazole and its active metabolite dehydro-aripiprazole to higher levels than normal metabolizers on the same dose, which translates into more side effects (akathisia, sedation, weight gain, metabolic shifts) at doses that would be well-tolerated by most patients. The FDA label for Abilify explicitly includes dose adjustment guidance for CYP2D6 poor metabolizers, making it one of the more prominent pharmacogenetic labels in psychiatry.
Aripiprazole is metabolized by CYP2D6 and CYP3A4. The primary clinically relevant genetic variation is in CYP2D6. The FDA label recommends administering half the usual dose in CYP2D6 poor metabolizers and reducing the dose further when aripiprazole is combined with strong CYP2D6 inhibitors (like fluoxetine or paroxetine, a real-world combination in psychiatric practice). For ultrarapid metabolizers, the concern is the opposite: standard doses may be cleared too quickly to maintain therapeutic effect, and higher doses or alternative antipsychotics may be considered.
Read the full aripiprazole genetics guide →Published guidance from FDA on how aripiprazole should be dosed or substituted based on your CYP2D6 phenotype.
| Phenotype | What it means | Recommendation | Evidence |
|---|---|---|---|
|
Ultrarapid Metabolizer
CYP2D6
|
Your body processes aripiprazole faster than normal. The standard dose should work as expected. |
FDA
Initiate therapy with recommended starting dose.
|
— |
|
Normal Metabolizer
CYP2D6
|
Your body processes aripiprazole at a normal rate. The standard dose should work as expected. |
FDA
Initiate therapy with recommended starting dose.
|
— |
|
Intermediate Metabolizer
CYP2D6
|
Your body breaks down aripiprazole slightly slower than normal. The standard dose should work as expected. |
FDA
Initiate therapy with recommended starting dose.
|
— |
|
Poor Metabolizer
CYP2D6
|
Your body breaks down aripiprazole much more slowly than normal, causing the drug to build up and increasing the risk of side effects. A lower dose is recommended. |
FDA
Reduce dose per FDA labeling due to higher systemic concentrations and increased adverse reaction risk.
|
Strong |
|
Indeterminate
CYP2D6
|
The impact of your genotype on response to this drug is unknown |
FDA
Initiate therapy with recommended starting dose.
|
— |
|
Not available
CYP2D6
|
The impact of your genotype on response to this drug is unknown |
FDA
Initiate therapy with recommended starting dose.
|
— |
Source: FDA
CYP2D6 is the most clinically important pharmacogene. It metabolizes around a quarter of all prescription drugs, including many antidepressants, opioids, and stimulants. The gene is unusually variable: roughly 7 percent of people are poor metabolizers (they barely activate CYP2D6), and another 1 to 3 percent are ultrarapid metabolizers (their enzyme is overactive).
For most CYP2D6 drugs, poor metabolizers feel stronger effects and more side effects at standard doses, while ultrarapid metabolizers may feel almost nothing. For prodrugs like codeine, the relationship flips: poor metabolizers feel less effect because they can't activate the drug.
Browse the full drug-class: Antipsychotics.
If Abilify is being added to your regimen, CYP2D6 testing is particularly useful for two reasons: it guides starting dose, and it flags drug-drug interactions that can change the effective CYP2D6 phenotype (a normal metabolizer on paroxetine effectively becomes a poor metabolizer because paroxetine inhibits CYP2D6). Many psychiatrists now test CYP2D6 proactively before starting any antipsychotic in this class, because the same gene affects several other second-generation antipsychotics (risperidone, iloperidone, brexpiprazole).
Yes. The long-acting injectable formulation still releases aripiprazole systemically, where it's cleared by CYP2D6 just as the oral form is. If anything, getting dose right matters more for the injectable because you can't abruptly stop it if side effects emerge. CYP2D6 testing before starting a long-acting injectable is especially worthwhile.
Akathisia (severe motor restlessness that many patients describe as agonizing) is a dose-related side effect of aripiprazole. Because CYP2D6 poor metabolizers accumulate the drug to higher plasma levels, they experience akathisia more often and at lower labeled doses than normal metabolizers. It's one of the most common reasons patients stop Abilify, and CYP2D6 status is often part of the explanation.
Largely yes. Brexpiprazole is a close structural relative of aripiprazole and is also cleared primarily by CYP2D6 and CYP3A4. The FDA label for Rexulti includes similar language about dose adjustment in CYP2D6 poor metabolizers. A CYP2D6 result is just as relevant to a brexpiprazole decision as it is to an aripiprazole decision.
This page describes the general pharmacogenetics. A Gene2Rx report analyzes your own DNA to tell you which metabolizer group you fall into, across every medication.
Get your report Look up another medicationInformational only — not medical advice. Pharmacogenetic guidance describes population-level patterns; your individual response depends on many factors. Never start, stop, or change a medication without talking to your prescribing clinician.